$62.85
0.11[0.18%]
At close: Apr 24
$62.85
0[0.00%]
After Hours: 4:00PM EDT
National Health Investors
(NYSE:NHI)National Health Investors Stock (NYSE:NHI), Analyst Ratings, Price Targets, Predictions
National Health Investors Inc has a consensus price target of $54, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Wedbush, and BMO Capital on April 4, 2024, March 18, 2024, and March 12, 2024. With an average price target of $63.67 between Truist Securities, Wedbush, and BMO Capital, there's an implied 1.30% upside for National Health Investors Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Wedbush
BMO Capital
Wells Fargo
Deutsche Bank
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for National Health Investors
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/04/2024 | NHI | Buy Now | National Health Investors | $62.85 | -7.72% | Truist Securities | Michael Lewis | $55 → $58 | Maintains | Hold | Get Alert |
| 03/18/2024 | NHI | Buy Now | National Health Investors | $62.85 | 5.01% | Wedbush | Richard Anderson | $64 → $66 | Maintains | Outperform | Get Alert |
| 03/12/2024 | NHI | Buy Now | National Health Investors | $62.85 | 6.6% | BMO Capital | Juan Sanabria | → $67 | Upgrade | Market Perform → Outperform | Get Alert |
| 02/26/2024 | NHI | Buy Now | National Health Investors | $62.85 | 1.83% | Wedbush | Richard Anderson | $57 → $64 | Upgrade | Neutral → Outperform | Get Alert |
| 02/26/2024 | NHI | Buy Now | National Health Investors | $62.85 | 0.24% | Wells Fargo | Connor Siversky | $55 → $63 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 01/30/2024 | NHI | Buy Now | National Health Investors | $62.85 | 9.79% | Deutsche Bank | Omotayo Okusanya | → $69 | Initiates | → Buy | Get Alert |
| 11/28/2023 | NHI | Buy Now | National Health Investors | $62.85 | -12.49% | Stifel | Stephen Manaker | → $55 | Reiterates | Hold → Hold | Get Alert |
| 11/27/2023 | NHI | Buy Now | National Health Investors | $62.85 | -12.49% | Wells Fargo | Todd Stender | $54 → $55 | Maintains | Equal-Weight | Get Alert |
| 10/03/2023 | NHI | Buy Now | National Health Investors | $62.85 | -14.08% | Wedbush | Richard Anderson | → $54 | Initiates | → Neutral | Get Alert |
| 09/28/2023 | NHI | Buy Now | National Health Investors | $62.85 | — | Berenberg | Conor Siversky | — | Initiates | → Hold | Get Alert |
| 09/20/2023 | NHI | Buy Now | National Health Investors | $62.85 | -17.26% | Jefferies | Joe Dickstein | → $52 | Initiates | → Hold | Get Alert |
| 05/11/2023 | NHI | Buy Now | National Health Investors | $62.85 | -14.08% | Wells Fargo | Todd Stender | $52 → $54 | Maintains | Equal-Weight | Get Alert |
| 03/29/2023 | NHI | Buy Now | National Health Investors | $62.85 | -20.45% | Credit Suisse | Omotayo Okusanya | $55 → $50 | Maintains | Neutral | Get Alert |
| 12/09/2022 | NHI | Buy Now | National Health Investors | $62.85 | -7.72% | Credit Suisse | Omotayo Okusanya | $47 → $58 | Upgrade | Underperform → Neutral | Get Alert |
| 09/26/2022 | NHI | Buy Now | National Health Investors | $62.85 | -2.94% | Truist Securities | Michael Lewis | $64 → $61 | Maintains | Hold | Get Alert |
| 06/21/2022 | NHI | Buy Now | National Health Investors | $62.85 | -1.35% | BMO Capital | John Kim | → $62 | Downgrade | Outperform → Market Perform | Get Alert |
| 04/19/2022 | NHI | Buy Now | National Health Investors | $62.85 | -2.94% | BMO Capital | John Kim | $63 → $61 | Maintains | Outperform | Get Alert |
| 02/01/2022 | NHI | Buy Now | National Health Investors | $62.85 | -18.85% | Credit Suisse | Tayo Okusanya | → $51 | Initiates | → Underperform | Get Alert |
| 01/07/2022 | NHI | Buy Now | National Health Investors | $62.85 | 8.19% | BMO Capital | John Kim | → $68 | Upgrade | Market Perform → Outperform | Get Alert |
FAQ
What is the target price for National Health Investors (NHI)?
The latest price target for National Health Investors (NYSE: NHI) was reported by Truist Securities on April 4, 2024. The analyst firm set a price target for $58.00 expecting NHI to fall to within 12 months (a possible -7.72% downside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for National Health Investors (NHI)?
The latest analyst rating for National Health Investors (NYSE: NHI) was provided by Truist Securities, and National Health Investors maintained their hold rating.
When was the last upgrade for National Health Investors (NHI)?
The last upgrade for National Health Investors Inc happened on March 12, 2024 when BMO Capital raised their price target to $67. BMO Capital previously had a market perform for National Health Investors Inc.
When was the last downgrade for National Health Investors (NHI)?
The last downgrade for National Health Investors Inc happened on June 21, 2022 when BMO Capital changed their price target from N/A to $62 for National Health Investors Inc.
When is the next analyst rating going to be posted or updated for National Health Investors (NHI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of National Health Investors, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for National Health Investors was filed on April 4, 2024 so you should expect the next rating to be made available sometime around April 4, 2025.
Is the Analyst Rating National Health Investors (NHI) correct?
While ratings are subjective and will change, the latest National Health Investors (NHI) rating was a maintained with a price target of $55.00 to $58.00. The current price National Health Investors (NHI) is trading at is $62.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.